Skip to main content
Journal cover image

Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes.

Publication ,  Journal Article
Younossi, ZM; Stepanova, M; Asselah, T; Foster, G; Patel, K; Bräu, N; Swain, M; Tran, T; Esteban, R; Colombo, M; Pianko, S; Henry, L; Bourliere, M
Published in: Clin Infect Dis
May 17, 2018

BACKGROUND: While the necessity of treatment of hepatitis C virus (HCV)-infected patients with advanced liver disease is widely accepted, the benefit of treating patients without significant liver disease is less well established. Our aim was to assess the effect of treating HCV in patients with no or minimal fibrosis (Metavir stage F0-F1) on patient-reported outcomes (PROs). METHODS: HCV-infected patients with F0-F1 from 16 clinical trials were included. PROs were collected before, during, and after treatment. RESULTS: A total of 1548 HCV-infected patients with F0-F1 were included (mean age 46 years, 43% male, 81% treatment-naive). Patients were treated with interferon (IFN) + sofosbuvir (SOF) + ribavirin (RBV) (n = 91) or SOF + RBV with or without ledipasvir (n = 479) or IFN- and RBV-free regimens with SOF + ledipasvir or SOF + velpatasvir or SOF + velpatasvir + voxilaprevir (n = 978). By the end of treatment, patients receiving IFN-containing regimens experienced significant decreases in most PRO domains (-4.5 to -28.7 on a 0-100 scale), while subjects treated with IFN-free RBV-containing regimens had a modest impairment (-2.3 to -8.9) (P ≤ .01). In contrast, treatment with regimens without IFN and RBV led to PRO improvements (+1.2 to +10.9). Regardless of the regimen, sustained virologic responses (SVRs) at 12 and 24 weeks were universally associated with PRO improvements (+2.1 to +14.7, P < .0001. CONCLUSIONS: HCV-infected subjects with no or minimal fibrosis treated with IFN- and RBV-free regimens experienced on-treatment and post-SVR PRO improvements.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Infect Dis

DOI

EISSN

1537-6591

Publication Date

May 17, 2018

Volume

66

Issue

11

Start / End Page

1742 / 1750

Location

United States

Related Subject Headings

  • Patient Reported Outcome Measures
  • Middle Aged
  • Microbiology
  • Male
  • Liver Cirrhosis
  • Humans
  • Hepatitis C
  • Female
  • Antiviral Agents
  • Adult
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Younossi, Z. M., Stepanova, M., Asselah, T., Foster, G., Patel, K., Bräu, N., … Bourliere, M. (2018). Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes. Clin Infect Dis, 66(11), 1742–1750. https://doi.org/10.1093/cid/cix1106
Younossi, Zobair M., Maria Stepanova, Tarik Asselah, Graham Foster, Keyur Patel, Norbert Bräu, Mark Swain, et al. “Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes.Clin Infect Dis 66, no. 11 (May 17, 2018): 1742–50. https://doi.org/10.1093/cid/cix1106.
Younossi ZM, Stepanova M, Asselah T, Foster G, Patel K, Bräu N, et al. Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes. Clin Infect Dis. 2018 May 17;66(11):1742–50.
Younossi, Zobair M., et al. “Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes.Clin Infect Dis, vol. 66, no. 11, May 2018, pp. 1742–50. Pubmed, doi:10.1093/cid/cix1106.
Younossi ZM, Stepanova M, Asselah T, Foster G, Patel K, Bräu N, Swain M, Tran T, Esteban R, Colombo M, Pianko S, Henry L, Bourliere M. Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes. Clin Infect Dis. 2018 May 17;66(11):1742–1750.
Journal cover image

Published In

Clin Infect Dis

DOI

EISSN

1537-6591

Publication Date

May 17, 2018

Volume

66

Issue

11

Start / End Page

1742 / 1750

Location

United States

Related Subject Headings

  • Patient Reported Outcome Measures
  • Middle Aged
  • Microbiology
  • Male
  • Liver Cirrhosis
  • Humans
  • Hepatitis C
  • Female
  • Antiviral Agents
  • Adult